StreetInsider.com News Articles

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Heading into Q3 earnings of MedTech stocks, analysts at BTIG recommend investors “use any weakness” to their advantage, focusing on names likely to reaccelerate early in 2027, even as the latest quarterly results are expected to face tougher comps as many companies had guided for higher growth in 2H26. Here, one name stands out.

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Nurix (NRIX) PT Raised to $36 at H.C. Wainwright

Fri, 16 Oct 2026 07:56:26 -0400

(Updated - October 16, 2026 7:56 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $34.00) while maintaining a Buy rating.

The analyst commented: "For F3Q26, Nurix reported a net gain of $4.73 per share and $673.1M in collaboration and license revenue. R&D and SG&A expenses were $79.3M and $34.4M, respectively, vs. our estimates of $83.3M and $15.8M; The increase in G&A expenses in the third quarter was primarily due to one-time expenses associated with the Roche transaction for consulting costs and business development activities. As of end-F3Q26, Nurix has approximately $1.1B in

Nurix (NRIX) PT Raised to $36 at H.C. Wainwright

Fri, 16 Oct 2026 07:56:26 -0400

(Updated - October 16, 2026 7:56 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $34.00) while maintaining a Buy rating.

Form 4 Nurix Therapeutics, Inc. For: Oct 15 Filed by: Hansen Gwenn

Thu, 15 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261015/27194060.html

Form 144 Nurix Therapeutics, Inc. Filed by: GREGORY JULIA P

Wed, 14 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261014/27187295.html

Form 4 Nurix Therapeutics, Inc. For: Oct 14 Filed by: GREGORY JULIA P

Wed, 14 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261014/27187234.html

Nurix (NRIX) PT Raised to $41 at Stifel Following Q3 Print

Tue, 13 Oct 2026 09:39:44 -0400

Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $41.00 (from $40.00) while maintaining a Buy rating.

The analyst commented, "We’re reiterating our Buy-rated thesis following management’s disclosure of 3QFY26 earnings and corporate update. We believe the Roche collaboration fundamentally improves the opportunity set for bexdeg – expanding the development footprint within CLL and providing the bandwidth/resources to pursue autoimmune and neurology applications where we anticipate BTK degradation can similarly achieve superior efficacy/safety vs. standard-of-care BTK inhibitors. We continue to believe the partnered I&I-focused pipeline remains underappreciated and believe KYMR’s YE26 disclosure of P2b BROADEN2 data (KT-621

Nurix (NRIX) PT Raised to $41 at Stifel Following Q3 Print

Tue, 13 Oct 2026 09:39:44 -0400

Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $41.00 (from $40.00) while maintaining a Buy rating.

Nurix (NRIX) PT Lowered to $35 at RBC Capital

Tue, 13 Oct 2026 09:20:56 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Nurix (NASDAQ: NRIX) to $35.00 (from $36.00) while maintaining an Outperform rating.

The analyst commented: "As Continues To Mature, Remains Underappreciated Story For Near- and Long-Term; Core programs remain on track, with bex-deg advancing in both single-arm ph.II and HTH ph.III CLL studies, the drug preparing to move into MS and CSU indications, STAT6 degrader '3911 moving into the clinic with SNY, and '1607 ph.I/II expanding; we believe this being the first reported quarter since the Roche deal close, coupled with the macro-related stock weakness, further underscores the company's underappreciated EV

Nurix (NRIX) PT Lowered to $35 at RBC Capital

Tue, 13 Oct 2026 09:20:56 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Nurix (NASDAQ: NRIX) to $35.00 (from $36.00) while maintaining an Outperform rating.

Nurix (NRIX) PT Lowered to $33 at Truist Securities

Tue, 13 Oct 2026 09:02:27 -0400

(Updated - October 13, 2026 9:02 AM EDT)

Truist Securities analyst Greg Renza lowered the price target on Nurix (NASDAQ: NRIX) to $33.00 (from $34.00) while maintaining a Buy rating.

The analyst commented: "NRIX's 3Q26 EPS and our 1x1 call reinforced progress across the lead bexdeg programs, with ph.III CLL-306 (H2H vs. pirto) and ph.Ib/II CLL-203 combination studies initiated, alongside planned I&I expansion into MS and CSU, under the Roche partnership. Beyond bexdeg, we see peer KT-621 (STAT6) ph.IIb data in late-Nov./early-Dec as a potential meaningful readthrough to NRIX/Sanofi's STAT6 program. Elsewhere, we view zelebrudomide's discontinuation as largely telegraphed given bexdeg prioritization,

Nurix (NRIX) PT Lowered to $33 at Truist Securities

Tue, 13 Oct 2026 09:02:27 -0400

(Updated - October 13, 2026 9:02 AM EDT)

Truist Securities analyst Greg Renza lowered the price target on Nurix (NASDAQ: NRIX) to $33.00 (from $34.00) while maintaining a Buy rating.

Nurix (NRIX) PT Raised to $32 at Oppenheimer

Tue, 13 Oct 2026 07:35:14 -0400

Oppenheimer analyst Kostas Biliouris raised the price target on Nurix (NASDAQ: NRIX) to $32.00 (from $28.00) while maintaining a Outperform rating.

Nurix (NRIX) PT Raised to $36 at Baird

Tue, 13 Oct 2026 07:23:42 -0400

Baird analyst Brian Skorney raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $33.00) while maintaining a Outperform rating.

Form 10-Q Nurix Therapeutics, Inc. For: Aug 31

Tue, 13 Oct 2026 06:21:00 -0400

si-local-file:///var/storage/secattach/20261013/27176494.html

Form 8-K Nurix Therapeutics, Inc. For: Oct 12

Tue, 13 Oct 2026 06:19:00 -0400

si-local-file:///var/storage/secattach/20261013/27176481.html

Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up

Mon, 12 Oct 2026 16:48:38 -0400

Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year. The company posted adjusted earnings per share of $4.73, compared to a loss of -$1.03 per share in the prior-year period. Shares are down 2% in after hours trading following the earnings release, though they were up nearly 8% shortly after.

The revenue surge was primarily driven by $653.2 million in license revenue from the company’s collaboration with Roche and a $10 million development milestone payment from Sanofi. During

Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up

Mon, 12 Oct 2026 16:48:38 -0400

The revenue surge was primarily driven by $653.2 million in license revenue from the company’s collaboration with Roche and a $10 million development milestone payment from Sanofi. During

Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73

Mon, 12 Oct 2026 16:17:31 -0400

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of $4.73, versus ($1.03) reported last year. Revenue for the quarter came in at $673.1 million, versus $7.9 million reported last year.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Mon, 12 Oct 2026 16:05:00 -0400

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study

Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial

Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with the first patient dosed in September 2026

Following receipt of the $700 million upfront as part of the close of

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Mon, 12 Oct 2026 16:05:00 -0400

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study

Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial

Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with the first patient dosed in September 2026

Following receipt of the $700 million upfront as part of the close of

Nurix enrolls first patient in bexobrutideg combination CLL study

Wed, 07 Oct 2026 01:00:15 -0400

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that the first patient has been enrolled in its Phase 1b/2 NX-5948-203 clinical trial evaluating bexobrutideg, an investigational oral BTK degrader, in combination with venetoclax for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The study is being conducted under a global collaboration between Nurix and Roche. It is designed to assess the safety, tolerability, and clinical activity of bexobrutideg combined with venetoclax, a BCL2 inhibitor. The initial cohort focuses on relapsed/refractory CLL, with potential expansion to first-line CLL patients.

The trial also plans to evaluate bexobrutideg in combination with the anti-CD20 antibodies rituximab and obinutuzumab